Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

(2016) Teru Hideshima   Therapeutics and Clinical Risk Management

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

(2009) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells

(2008) G. Heller et al.   CANCER RESEARCH

How tumours escape mass destruction

(2008) T J Stewart et al.   ONCOGENE

Inteferons pen the JAK–STAT pathway

(2008) Christian Schindler et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

SOCS regulation of the JAK/STAT signalling pathway

(2008) Ben A. Croker et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY